



PARTICIPANT STATISTICS

FIRST QUADRIMESTER 2017

HIV MARKERS

anti-HIV-1 or 1/2 Screening

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
*Abbott Architect HIV Ag/Ab		14		14			14			14			13		1
Alere Clearview Complete HIV 1/2		13		13			13			12			13		
*Alere Determine	1	124		124	1		124	1		2	123		122	3	
*Bio-Rad GS HIV Combo Ag/Ab EIA	1	14		1	14		15			1	14		15		
Bio-Rad HIV-1/2 Plus O EIA		8		5	3		8			8			8		
Chembio HIV 1/2 STAT-PAK		5		5			5			5			5		
Clearview Stat-Pak		5		5			5			5			5		
OraSure OraQuick Advance		6		6			6			6			6		
Trinity Uni-Gold Recombigen		9		9			9			9			9		
Total Population	2	214	0	194	22	0	215	1	0	3	212	0	212	4	0
Flagging	***		***		**&	***		***	***	***	***	***	***	***	***

& 4th Generation Ag/Ab Combo kits reacted to the p24 antigen as would be expected. They were evaluated against both antigen and antibody. If your kit reports serology and antigen independently, you must report antigen detection separately or be flagged.

anti-HIV-1 or 1/2 Confirmation

Method	Specimen 1				Specimen 2									
	Neg	Pos	Ind	Pos HIV 1/Neg HIV2	Neg HIV 1/Neg HIV2	Pos HIV 1/Pos HIV2	Neg, TNP	Neg	Pos	Ind	Pos HIV 1/Neg HIV2	Neg HIV 1/Neg HIV2	Pos HIV 1/Pos HIV2	Neg, TNP
Bio-Rad Geenius		1		8				1				8		
Trinity Uni-Gold Recombigen		33	1					10						1
Total Population	0	37	1	10	0	0	0	14	0	0	0	10	0	1
Flagging	***		***		***	***	***	***	***	***	***	***	***	***

anti-HIV-1 or 1/2 Confirmation

Method	Specimen 3				Specimen 4									
	Neg	Pos	Ind	Pos HIV 1/Neg HIV2	Neg HIV 1/Neg HIV2	Pos HIV 1/Pos HIV2	Neg, TNP	Neg	Pos	Ind	Pos HIV 1/Neg HIV2	Neg HIV 1/Neg HIV2	Pos HIV 1/Pos HIV2	Neg, TNP
Bio-Rad Geenius	1				7			1		1		8		
Trinity Uni-Gold Recombigen	10							1	33		1			
Total Population	14	0	0	0	8	0	3	0	38	1	10	0	0	0
Flagging		***	***	***		***		***		***		***	***	***

anti-HIV-1 or 1/2 Confirmation

Method	Specimen 5						
	Neg	Pos	Ind	Pos HIV 1/Neg HIV2	Neg HIV 1/Neg HIV2	Pos HIV 1/Pos HIV2	Neg, TNP
Bio-Rad Geenius	1				7		1
Trinity Uni-Gold Recombigen	8	2					1
Total Population	12	2	0	0	8	0	3
Flagging		***	***	***		***	

p24 Antigen

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind	Neg	Pos	Ind
Alere Determine	125	2		120	7		121	1		118	4		121	1	
Total Population	128	5	0	124	9	0	127	1	0	121	7	0	127	1	0
Flagging		***	***					***	***		***	***		***	***

*Specimen 2 was not evaluated this event. The intended result was positive.

NOTE: Many laboratories using 4th generation Antigen/Antibody screening methods reported both Antigen and Antibody results in the anti-HIV result line. You must report the antibody reactivity in the anti-HIV line and the antigen detection in the p24 Antigen line. If your kit detects primary antigens other than p24, please contact us so we may evaluate your method appropriately. Kits which report only a positive result without discrimination were not penalized and evaluated as if they reported a generic HIV result. If your kit reports separately for the detection of antibody and antigen, you must report as such.

Also, we noted that many laboratories reporting early detection antigen screen methods, also reported Western Blot confirmation and as such failed to confirm their positive screen results. If your laboratory is running a 4th generation early detection antigen method you need to be aware that a standard serology based confirmation method will fail to confirm a positive result. Please be sure that your laboratory protocol is appropriate to confirm results obtained using an HIV Antigen Screen.

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.